Eris Lifesciences Limited - Q4 FY25 Results

Eris Lifesciences Limited, a leading Indian branded formulations manufacturing company, today announced its earnings for the fourth quarter and full year FY25.

Consolidated Financial Highlights:

Commenting on the results, Amit Bakshi, Chairman & Managing Director of Eris Lifesciences Ltd., said, “Our Branded Formulations business has delivered a 10 percent organic growth in Q4. Our Diabesity strategy is progressing in line with our expectations and we have created an exciting pipeline in Insulins, Analogues and GLPs. We will take the lead in ensuring continued supply of life-saving insulins to patients across the country following the impending exit of the innovator from the RHI Penfill market. With our FY23 and FY24 investments fully integrated and growth-ready, we look forward to an exciting phase of secular growth over the next 3 years.”

 Krishnakumar Vaidyanathan, Executive Director & Chief Operating Officer added, “We have realised significant operating margin improvements in our DBF business due to synergies from business integration and rapid progress in insourcing of manufacturing, including the start of insulin production from our Bhopal facility. We have made significant investments in Swiss Parenterals to create new revenue streams, the full potential of which will start getting realised from FY27. We are entering a 3-year period of secular organic growth with significant inflection expected in our EPS and ROCE trajectories.”

Q4FY25 and FY25 - Financial Highlights

·         Revenue of Q4 FY 25 grew by 28 percent YoY to Rs. 705 Crore and FY 25 grew by 44 percent YoY to Rs. 2,894 Crore

·         EBITDA for Q4 FY 25 is Rs. 252 Crore, with 36 percent EBITDA margin and FY 25 is INR 1,017 Crore with 35 percent EBITDA margin

·         PAT for Q4 FY 25 is Rs. 102 Crore with 14 percent PAT margin and FY 25 is Rs. 375 Crore with 13 percent PAT margin

·         Operating Cash flows are 111 percent of EBITDA in Q4 and 105 percent of EBITDA in FY 25

·         Net Debt as on 31 March is ~Rs. 2,222 Crore

Also Read: Personalized Medicine: Get Tailored Treatment Plans for You Now

FY25 - Business Highlights

·         Organic Domestic Branded Formulations business grew by 9 percent yoy

·         Domestic Branded Formulations segment revenue grew by 32 percent yoy and EBITDA margin grew by 207 bps

·         15 out of Top-25 mother brands ranks among Top-5 in their respective markets with revenues of 5 mother brands above Rs. 100 Crores.